M&A Deal Summary

Perrigo Company Acquires Elan

On December 18, 2013, Perrigo Company acquired healthcare services company Elan for 8.6B USD

Acquisition Highlights
  • This is Perrigo Company’s 3rd transaction in the Healthcare Services sector.
  • This is Perrigo Company’s largest (disclosed) transaction.
  • This is Perrigo Company’s 1st transaction in Ireland.

M&A Deal Summary
Date 2013-12-18
Target Elan
Sector Healthcare Services
Buyer(s) Perrigo Company
Deal Type Add-on Acquisition
Deal Value 8.6B USD

Target

Elan

Dublin, Ireland
Elan is a biotechnology company, headquartered in Dublin, Ireland, committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. It focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases.

Search 200,050 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Perrigo Company

Dublin 2, Ireland
Category Company
Founded 1887
Sector Life Science
Employees9,140
Revenue 4.7B USD (2023)
DESCRIPTION
Entrance to a Perrigo facility in Duncan, South Carolina.
Entrance to a Perrigo facility in Duncan, South Carolina.

Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. The company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo Company was founded in 1887 and is based in Dublin, Ireland.

DEAL STATS #
Overall 20 of 31
Sector (Healthcare Services) 3 of 3
Type (Add-on Acquisition) 17 of 23
Country (Ireland) 1 of 1
Year (2013) 4 of 4
Size (of disclosed) 1 of 23
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-06-17 Fera Pharmaceuticals - Ophthalmic Ointments

Melville, New York, United States

Fera Pharmaceuticals - Ophthalmic Ointments is a provider of anti-infective ophthalmic drugs.

Buy $93M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-02-28 OTC Products

Grand Bay, Mauritius

OTC Products are primarily sold through the mass retail channel and include the Herron® range of analgesics, vitamins and supplements. This basket of products is expected to generate at least $20 million in annual revenue.

Buy $51M
Mergr

Product

Company

Legal